Skip to main content

Alnylam Starts Phase I Trial of Subcutaneous ATTR Drug

Premium

Alnylam Pharmaceuticals this week announced that it has started a phase I trial of its subcutaneous TTR-mediated amyloidosis treatment ALN-TTRsc.

The study is being conducted in the UK and will examine single and multiple escalating doses of the drug in up to 40 healthy volunteers.

The trial’s primary endpoints are safety and tolerability, and secondary objectives include assessment of clinical activity as measured by serum levels of the TTR protein. Data is expected to be available by mid-year, Alnylam said.

As previously disclosed, a phase II trial of ALN-TTRsc is slated to begin before the end of 2013, with a pivotal trial on track for 2014.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.